Phase I study of the antiprogrammed cell death‐1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies

Spartalizumab is a humanized IgG4/κ mAb directed against human programmed cell death‐1 (PD‐1). In this phase I study, we investigated safety, pharmacokinetics, preliminary antitumor activity, and toxicity of spartalizumab in patients with advanced malignancies. Patients (n = 18) with a range of tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Minami, Hironobu, Doi, Toshihiko, Toyoda, Masanori, Imamura, Yoshinori, Kiyota, Naomi, Mitsuma, Ayako, Shimokata, Tomoya, Naito, Yoichi, Matsubara, Nobuaki, Tajima, Takeshi, Tokushige, Kota, Ishihara, Kae, Cameron, Scott, Ando, Yuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893979/
https://www.ncbi.nlm.nih.gov/pubmed/33031626
http://dx.doi.org/10.1111/cas.14678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893979/
https://www.ncbi.nlm.nih.gov/pubmed/33031626
http://dx.doi.org/10.1111/cas.14678

Ejemplares similares